Captopril mitigates splenomegaly and myelofibrosis in the Gata1^low murine model of myelofibrosis.

ABSTRACT: Allogeneic stem cell transplantation is currently the only curative therapy for primary myelofibrosis (MF), while the JAK2 inhibitor, ruxolitinib. Has been approved only for palliation. Other therapies are desperately needed to reverse life-threatening MF. However, the cell(s) and cytokine(s) that promote MF remain unclear. Several reports have demonstrated that captopril, an inhibitor of angiotensin-converting enzyme that blocks the production of angiotensin II (Ang II), mitigates fibrosis in heart, lung, skin and kidney. Here, we show that captopril can mitigate the development of MF in the Gata1^low mouse model of primary MF. Gata1^low mice were treated with 79 mg/kg/d captopril in the drinking water from 10 to 12 months of age. At 13 months of age, bone marrows were

SUBMITTER: Corey SJ 

PROVIDER: S-EPMC6111823 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature